Corporation announced that additional in vitro mechanistic data with eicosapentaenoic acid, EPA, will be presented at the ...

After stock crash and staff cuts, Amarin wins bid to revive Vascepa patent lawsuit The complaint comes after Sarissa successfully won shareholders’ support to replace seven of Amarin’s board ...

Corporation highlighted key data presentations at ACC.25 showcasing the mechanistic activity of eicosapentaenoic acid, EPA, on ...

as well as our plans and strategies for entering into potential strategic collaboration and licensing agreements and the overall potential and future success of VASCEPA/VAZKEPA and Amarin that are ...

And Steve Ketchum, Amarin's Executive Vice President, President of R&D and Chief Scientific Officer will provide an update on recent and upcoming VASCEPA/VAZKEPA research. And at the end of the ...

And Steve Ketchum, Amarin's Executive Vice President, President of R&D and Chief Scientific Officer will provide an update on recent and upcoming VASCEPA/VAZKEPA research. And at the end of the ...

DUBLIN and BRIDGEWATER, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ ... branded revenue in the U.S. market for VASCEPA, unlocked access to VASCEPA/VAZKEPA in six ...